RESEARCH ARTICLE


Computational Pharmacogenetics of P-Glycoprotein Mediated Antiepileptic Drug Resistance



Sindhu Varghese1, Ashok Palaniappan2, *
1 Department of Allied Health Sciences, Chettinad Academy of Research and Education, Kelambakkam, Tamil Nadu 603103, India
2 School of Chemical and Biotechnology, SASTRA Deemed University, Thanjavur, Tamil Nadu 613401, India


Article Metrics

CrossRef Citations:
1
Total Statistics:

Full-Text HTML Views: 2445
Abstract HTML Views: 1434
PDF Downloads: 554
ePub Downloads: 460
Total Views/Downloads: 4893
Unique Statistics:

Full-Text HTML Views: 1312
Abstract HTML Views: 879
PDF Downloads: 427
ePub Downloads: 343
Total Views/Downloads: 2961



Creative Commons License
© 2018 Varghese and Palaniappan.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (https://creativecommons.org/licenses/by/4.0/legalcode). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to the author at the School of Chemical and Biotechnology, SASTRA Deemed University, Thanjavur, Tamil Nadu 613401, India; E-mail: apalania@scbt.sastra.edu


Abstract

Background:

The treatment of epilepsy using antiepileptogenic drugs is complicated by drug resistance, resulting in treatment failure in more than one-third of cases. Human P-glycoprotein (hPGP; MDR1) is a known epileptogenic mediator.

Methods:

Given that experimental investigations have suggested a role for pharmacogenetics in this treatment failure, it would be of interest to study hPGP polymorphisms that might contribute to the emergence of drug resistance. Changes in protein functional activity could result from mutations as well as altered abundance. Bioinformatics approaches were used to assess and rank the functional impact of 20 missense MDR1 polymorphisms and the top five were selected. The structures of the wildtype and variant hPGP were modelled based on the mouse PGP structure. Docking studies of the wildtype and variant hPGP with four standard anti-epileptic drugs were carried out.

Results:

Our results revealed that the drug binding site with respect to the wildtype protein was uniform. However, the variant hPGP proteins displayed a repertoire of binding sites with stronger binding affinities towards the drug.

Conclusion:

Our studies indicated that specific polymorphisms in MDR1 could drive conformational changes of PGP structure, facilitating altered contacts with drug-substrates and thus modifying their bioavailability. This suggests that MDR1 polymorphisms could actively contribute to the emergence of pharmaco-resistance in antiepileptic therapy.

Keywords: P-glycoprotein, Drug-resistant epilepsy, MDR1 polymorphism, Structure-activity relationship, Docking, Homology modelling, Differential ligand affinity, Bioavailability.